04/17/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
3:24 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/10/2024
10:58 AM | Capital International Investors (Filed by)
CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
04/09/2024
3:42 PM | CRISPR Therapeutics (Filer)
| Form DEF 14A | |
04/09/2024
3:43 PM | CRISPR Therapeutics (Filer)
| Form DEFA14A | |
04/09/2024
3:47 PM | CRISPR Therapeutics (Filer)
| Form ARS | |
03/27/2024
3:30 PM | CRISPR Therapeutics (Filer)
| Form PRE 14A | |
|
03/27/2024
3:30 PM | CRISPR Therapeutics (Filer)
| Form PRE 14A | |
03/22/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/22/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/22/2024
4:45 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/22/2024
3:02 PM | CRISPR Therapeutics (Subject)
Morrow Phuong Khanh (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/18/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
3:43 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/12/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/12/2024
4:45 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2024
5:39 PM | CRISPR Therapeutics (Issuer)
George Simeon (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2024
4:45 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2024
6:45 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/21/2024
6:50 AM | CRISPR Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/16/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/15/2024
3:30 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/13/2024
4:22 PM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/13/2024
7:44 AM | CRISPR Therapeutics (Filer)
| Form 424B5 | |
02/13/2024
5:30 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/13/2024
5:30 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/12/2024
5:22 PM | CRISPR Therapeutics (Subject)
Nikko Asset Management Americas, Inc. (Filed by)
| Form SC 13G/A | |
02/05/2024
5:08 AM | CRISPR Therapeutics (Subject)
Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
| Form SC 13G/A | |
01/31/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
3:00 PM | ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
01/18/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2024
10:36 AM | ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
12/15/2023
7:58 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/13/2023
8:22 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/08/2023
12:16 PM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/16/2023
6:21 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2023
3:42 PM | CRISPR Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2023
3:33 PM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2023
4:52 PM | CRISPR Therapeutics (Issuer)
Morrow Phuong Khanh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Did You Get Your Free Bitcoin Yet? (Ad) And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here |
10/17/2023
4:52 PM | CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2023
4:48 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2023
4:51 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/07/2023
7:39 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/09/2023
4:33 PM | CRISPR Therapeutics (Issuer)
Fardis Maria (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:34 PM | CRISPR Therapeutics (Issuer)
Fleming Harold Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:34 PM | CRISPR Therapeutics (Issuer)
Greene John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:36 PM | CRISPR Therapeutics (Issuer)
High Katherine A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:36 PM | CRISPR Therapeutics (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:48 PM | Behbahani Ali (Reporting)
CRISPR Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:56 PM | CRISPR Therapeutics (Issuer)
George Simeon (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
6:07 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/01/2023
4:44 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2023
3:38 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/25/2023
4:35 PM | CRISPR Therapeutics (Issuer)
Morrow Phuong Khanh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2023
2:23 PM | CRISPR Therapeutics (Subject)
Smith Brendan (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/27/2023
4:37 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2023
3:38 PM | CRISPR Therapeutics (Filer)
| Form ARS | |
04/25/2023
3:28 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
